Wang Fangqing

Oct 4, 2024 | finance.yahoo.com | Wang Fangqing

Chinese Breakfast Cereal Market: Slow but Steady Growth China has been a key target for multinational food companies for decades but success has varied by category. Western-style breakfast cereal has not made the advances seen in other parts of the industry but, as Wang Fangqing reports, that is gradually changing. The Chinese market for breakfast foods has long been dominated by traditional meals.

May 21, 2024 | thepharmaletter.com | Wang Fangqing

Given that the USA’s House Committee on Oversight and Accountability held a markup meeting last week on the legislation, it is likely that the USA will pass the BIOSECURE Act (the Act) in December this year.

Apr 8, 2024 | thepharmaletter.com | Wang Fangqing

Two frequent words that people often hear in recent China’s pharma industry comments are “Chu Hai” and “Nei Juan”. The former means “selling overseas,” while the latter means “cut throat competition.” Competition is no doubt fierce in China. Take GLP1 receptor agonists (GLP RA) as an example. The popular diabetes treatment that doubles as a weight loss drug now has over 200 candidates in clinical…This article is accessible to registered users, to continue reading please register for free.

Mar 26, 2024 | thepharmaletter.com | Wang Fangqing

Much like in the West, biotechs in China also recently started to see cash again after a cold spell in the past two years. Promising, late-stage assets are most attractive to investors, especially Chinese state-owned venture capitals, said speakers at Bio China International Convention in Suzhou. “Chinese yuan denominated funds, now the major investors in China, are usually owned by state-owned capitals.

Mar 13, 2024 | thepharmaletter.com | Wang Fangqing

Once dubbed as me-too copycats and fast followers, Chinese biotechs are flocking to innovation mix, or combinatorial innovation, hoping to discover a novel therapy based on a mixture of existing resources, according to the consulting firm Clarivate Analytics.